Visiongain will be holding its 7th Annual Biosimilars Conference on October 5-7, 2010 in London, UK. The conference will allow attendees to:
• Gain insights of the competitive landscape in biosimilars: U.S., EU, and emerging markets;
• Evaluate biobetters and differentiated biosimilars as practical alternatives to biosimilars for regulated markets;
• Implement successful commercial models for biobetters and follow-on biological medicines;
• Review the global pricing and reimbursement models in the biosimilars and generics market;
• Learn the impact on biosimilars product patenting;
• Leverage licensing opportunities for biosimilars;
• Validate biomarkers and comparative immunogenicity as surrogate endpoints; and
• Explore technologies for producing improved biologics: Drug delivery, half-life extension, cell production, and glycoengineering methods.
At the conference, Visiongain faculty will offer presentations on the following topics on October 6-7:
• Understanding the competitive landscape in biosimilars;
• Overview of Japanese regulatory framework on biosimilars: Trends, opportunities and challenges;
• Impact of healthcare reform on biosimilars in global biosimilars development;
• Biosimilar erythropoietin: Uptake in Europe;
• Biosimilars: Between innovator biomedicines and classical generics;
• Comparability evaluation of biological products;
• Comparability, biosimilars, "interchangeable biosimilars," and current U.S. legislation;
• Unwanted immunogenicity of biologicals and biosimilars;
• Immunogenicity testing of biosimilars and biobetters;
• Developing a long term commercial strategy for biosimilars;
• Revolutionizing biosimilar development in the EU market;
• Strategic marketing implications of biosimilars;
• Believing in biobetters: Half-life and antigenicity;
• Rising to the challenge of developing biosimilar monoclonals;
• Panel Discussion: The regulatory approaches to chemicals and biologicals -- Is it time that the "Process is the Product" finally died?"
• Emerging markets: A spotlight on Asia.
In addition, a pre-conference workshop entitled "Patent issues in the development of biosimilar medicines" will be offered on October 5. The pre-conference workshop will comprise two parts, with Part 1 focusing on the European perspective and Part 2 focusing on the U.S. perspective.
The agenda for the Biosimilars Conference can be found here. A complete brochure for this conference, including an agenda, list of speakers, and registration form can be downloaded here (free registration required).
The registration fee ranges from £1299 ($2,030.64) for the conference alone to £1699 ($2,655.93) for the conference and workshop; the fee for attending the workshop alone is £599 ($936.38), excluding VAT. Those interested in registering for the conference can do so here.
Comments